Publications by authors named "S Bhoi"

Utilizing the soft-lattice nature of metal halide perovskites, we employ post-synthetic cross-ion exchange to synthesize a series of narrow band-gap colloidal nanocrystals of methylammonium-based lead iodide solid solutions of composition FAMAPbI, as well as those of triple-cation composition CsFAMAPbI (TCPbI). The ability to finely tune the compositions not only helps in tailoring the optical properties in the near-infrared region, but also improves the stability of these colloidal nanocrystals towards moisture, which has been demonstrated as compared to their bulk counterparts. The thermal stability of these solid solutions is also comparable to that of the bulk, as evidenced by thermogravimetric studies.

View Article and Find Full Text PDF

Earlier studies have proved deteriorating Glasgow Coma Scale (GCS) as a marker of raised intracranial pressure (ICP). Low GCS is associated with abnormal pupillary parameters. Currently, many studies have proved that ultrasound provides a feasible and objective assessment of pupillary light reflex.

View Article and Find Full Text PDF

Rationale: Early mortality in intracerebral hemorrhage (ICH) is due to hematoma volume (HV) expansion, and there are no effective treatments available other than reduction in blood pressure. Tranexamic acid (TXA) a hemostatic drug that is widely available and safe can be a cost-effective treatment for ICH, if proven efficacious.

Hypothesis: Administration of TXA in ICH patients when given within 4.

View Article and Find Full Text PDF

Background: Hypoglycemia is a serious, often overlooked complication of treating hyperkalemia with insulin and dextrose. If not recognized and managed, it can increase morbidity and mortality. This study aimed to estimate the incidence of hypoglycemia in hyperkalemic patients treated with 10 units of intravenous insulin, 50 ml of 50% dextrose, 10 ml of 10% calcium gluconate, and salbutamol nebulization.

View Article and Find Full Text PDF

Purpose: To evaluate safety, preliminary efficacy, pharmacokinetics, and pharmacodynamics, of fostroxacitabine bralpamide (fostrox, MIV-818), a novel oral troxacitabine nucleotide prodrug designed to direct exposure to the liver, while minimizing systemic toxicity.

Patients And Methods: Fostrox monotherapy was administered in an open-label, single-arm, first-in-human, phase 1a/1b study, in patients with hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma, or solid tumor liver metastases. The first part (1a) consisted of intra/inter-patient escalating doses (3 mg to 70 mg) QD for up to 5 days, and the second part (1b), doses of 40 mg QD for 5 days, in 21-day cycles.

View Article and Find Full Text PDF